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Abstract
Purpose 53BP1 foci detection in peripheral blood lymphocytes (PBLs) by immunofluorescence microscopy (IFM) is
a sensitive and quantifiable DNA double-strand break (DSB) marker. In addition, high-resolution transmission electron
microscopy (TEM) with immunogold labeling of 53BP1 and DSB-bound phosphorylated Ku70 (pKu70) can be used to
determine the progression of the DNA repair process. To establish this TEM method in the PBLs of patients with cancer,
we analyzed and characterized whether different modes of irradiation influence the formation of DSBs, and whether
accompanying chemotherapy influences DSB formation.
Methods We obtained 86 blood samples before and 0.1, 0.5, and 24h after irradiation from patients (n= 9) with head and
neck or rectal cancers receiving radiotherapy (RT; n= 4) or radiochemotherapy (RCT; n= 5). 53BP1 foci were quantified
by IFM. In addition, TEM was used to quantify gold-labelled pKu70 dimers and 53BP1 clusters within euchromatin and
heterochromatin of PBLs.
Results IFM analyses showed that during radiation therapy, persistent 53BP1 foci in PBLs accumulated with increasing
numbers of administered RT fractions. This 53BP1 foci accumulation was not influenced by the irradiation technique applied
(3D conformal radiotherapy versus intensity-modulated radiotherapy), dose intensity per fraction, number of irradiation
fields, or isodose volume. However, more 53BP1 foci were detected in PBLs of patients treated with accompanying
chemotherapy. TEM analyses showed that DSBs, indicated by pKu70, were present for longer periods in PBLs of RCT
patients than in PBLs of RT only patients. Moreover, not every residual 53BP1 focus was equivalent to a remaining DSB,
since pKu70 was not present at every damage site. Persistent 53BP1 clusters, visualized by TEM, without colocalizing
pKu70 likely indicate chromatin alterations after repair completion or, possibly, defective repair.
Conclusion IFM 53BP1 foci analyses alone are not adequate to determine individual repair capacity after irradiation of
PBLs, as a DSB may be indicated by a 53BP1 focus but not every 53BP1 focus represents a DSB.
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Introduction
The effects of radiotherapy (RT) in cancer treatment can
be significantly enhanced by simultaneous chemotherapy
[1]. The action of both seems to depend on their ability to
induce mutagenic and clastogenic DNA damage, includ-
ing crosslinks, strand breaks, replication errors, and base
adducts [2, 3], which can induce cell death. Precise dose
distributions to the planning target volume (PTV) by highly
conformal techniques are critical for minimizing side ef-
fects in adjacent organs at risk.
DNA damage repair mechanisms protect against adverse
effects of carcinogenic therapies. While the likelihood
of RT-induced side effects in organs at risk can be reli-
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ably assessed by dosimetric calculations, peripheral blood
lymphocytes (PBL), especially in patients who received ra-
diochemotherapy (RCT), are exposed to an erratic amount
of events that may cause DNA damage. Double-strand
break (DSB) repair is crucial for PBL survival following
RT or RCT-induced DNA damaging effects. During non-
homologous end joining (NHEJ), the major mammalian
DSB repair pathway, the Ku70–Ku80 heterodimer recog-
nizes DSBs and maintains the broken DNA ends in close
proximity until the DSB is rejoined [4]. In addition, the
phosphorylated histone variant of H2AX, γH2AX, recruits
repair proteins such as 53 binding protein 1 (53BP1) to the
chromatin surrounding the DSB [5, 6]. 53BP1 is an im-
portant regulator in the cellular damage response to DSBs,
promoting the binding of the distal DNA ends which occurs
during variable diversity joining (V(D)J), class-switch re-
combination (CSR), or fusion of the unprotected telomeres.
Recruitment of 53BP1 to the site of damaged chromatin
also promotes nonhomologous end joining-mediated DSB
repair (NHEJ) while preventing homologous recombination
(HR) [7–10]. Specific primary and fluorescent secondary
antibodies against 53BP1 localized to DSB repair foci [8,
11] may be used as markers to quantify DSB repair by
immunofluorescence microscopy (IFM).
Assuming that each 53BP1 focus corresponds to one
DSB, the number of foci in the nucleus can be applied
to measure DNA damage caused by radiation exposure
[12–18]. PBLs are suitable to assess the DNA damage re-
sponse of patients, as peripheral blood samples can be taken
repeatedly and at defined timepoints after irradiation. In ad-
dition, the hematopoietic system is radiosensitive and lym-
phocytes and their subpopulations are well characterized in
terms of phenotype and function [19–22] and can be reli-
ably isolated from blood [23]. Moreover, PBLs are in the
resting state (G0) of the cell cycle [24, 25], thereby resulting
in a prolonged presence of DNA damage [26–28].
Due to the limited resolution of IFM, 53BP1 visualiza-
tion does not provide full-scale information regarding indi-
vidual repair points and radiation sensitivity. Additionally,
individual repair proteins of the Ku70–Ku80 heterodimer
cannot be detected as their fluorescence is not sufficient
to differentiate them from the background signal. The de-
tection of both 53BP1 and the DSB-bound phosphorylated
Ku70 (pKu70) would signal incomplete NHEJ repair sites.
Here, high-resolution transmission electron microscopy
(TEM) with gold-labeled pKu70 and 53BP1 [29, 30] was
used to determine the suitability of this analysis for assess-
ing individual PBL radiation sensitivity in patients with
different tumor entities (head and neck or rectal cancers),
isodose volumes, irradiation techniques (intensity modu-
lated radiotherapy, IMRT or 3D-conformal RT, 3D-CRT),
and treatment approaches (RT or RCT).
Materials andmethods
Patients and treatment conditions
This study was conducted in accordance with the Helsinki
declaration and with approval of the local ethics committee
(Ärztekammer des Saarlandes). All patients (n= 9) signed
written informed consent forms. Patients meeting the fol-
lowing inclusion criteria were enrolled between March
2011 and May 2012: Aged between 18 and 80 years;
Karnofsky index >70%; completely resected head and neck
squamous cell cancer (oral cavity, oropharynx, hypophar-
ynx, or larynx) with postoperative RT indicated with or
without chemotherapy; or diagnosis of rectal cancer with
an indication for neoadjuvant or adjuvant pelvic radiother-
apy (with or without chemotherapy). Patients with previous
RT or chemotherapy and those with distant metastases were
excluded.
All patients underwent standard computed tomography-
based RT planning with 3D-conformal target volume de-
lineation. IMRT with a predefined PTV arrangement of
seven coplanar beam angles with 70 beam segments and
standardized objectives based on the ICRU Report 83 [31]
and constraints for normal tissues (brainstem, spinal cord,
parotid glands, esophagus) based on QUANTEC data [32]
with individualized clinical assessments was mandatory for
patients with head and neck cancer (n= 4). A 60Gy ref-
erence dose was prescribed to primary tumor sites and
lymph node metastases in cervical regions and 50Gy to
non-involved cervical and supraclavicular lymph node re-
gions. Single doses were 2.0Gy, once daily, 5 days a week.
Concomitant chemotherapy, if prescribed, included two cy-
cles of cisplatin (20mg/m2 intravenously over 0.5h, D1–5;
D29–33) and two cycles of 5-fluorouracil (600mg/m2 in-
travenously over 24h, D1–5; D29–33). Patients with rectal
cancer (n= 5) were treated in a prone position on a belly
board by means of three 3D-conformal coplanar portals
(0°, 90°, 270°) with a total reference dose of 50.4Gy (op-
tional 5.4Gy boost to the primary tumor after 45Gy) and
a single dose of 1.8Gy (once daily, 5 fractions/week). Con-
current neoadjuvant chemotherapy consisted of two cy-
cles of 5-fluorouracil (1000mg/m2 intravenously over 24h,
D1–5; D29–33). Adjuvant 5-fluorouracil was administered
as a continuous infusion of 225mg/m2 (D1–38). All pa-
tients were irradiated with a linear accelerator (ONCOR™
or ARTISTE™) from Siemens (Erlangen, Germany), using
photons of 6 MV for IMRT of head and neck cancers or
18 MV for 3D-CRT of rectal cancers. The analysis of RT-
related parameters included assessment of blood volume
contained within the 50% isodose line (derived from vol-
umetric computation of delineated blood vessels >1cm in
diameter), body volumes surrounded by the 10Gy, 20Gy,
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30Gy, and 45Gy isodose lines (V10iso–V45iso), and cover-
age of the PTV (D80, D90).
Blood sampling
For IFM analysis, blood samples were collected from
a cubital vein in heparin-containing vials at 37°C and di-
luted 1:2 with prewarmed Roswell Park Memorial Institute
(RPMI) 1640 medium (Biochrom; Berlin, Germany) for
immediate processing. All patient samples were obtained
immediately before and 0.5h after the first RT fraction
(control and induction values, respectively) and 24h after
the first and fourth RT fractions in weeks 1, 2, 4, and 6
(after fractions 1, 4, 6, 9, 16, 19, and 26; and after fraction
29 in head and neck cancer samples).
To perform TEM analysis, blood samples were collected
directly before and 0.1, 0.5, and 24h after the first RT frac-
tion for immediate processing.
For ex vivo experiments, blood from healthy donors was
obtained, PBLs isolated, homogeneously irradiated, and in-
cubated in RPMI at 37°C.
Dose dependence
PBLs were suspended in cold phosphate-buffered saline
(PBS), irradiated with different doses (0.5, 1.0, 2.0, or
4.0Gy), and suspended in RMPI medium (Sigma-Aldrich,
St. Louis, MO, USA) prior to a 0.5h incubation at 37°C
allowing for repair.
Time course
Following irradiation with 1.0Gy, PBLs were incubated in
RPMI medium at 37°C, and fixated 0.1, 0.25, 2.5, 8.0, and
24h after irradiation. Nonirradiated PBLs from the same
donor served as control.
Blood sample preparation for IFM and TEM
Briefly, blood samples in heparin tubes were diluted with
6ml RPMI and incubated at 37°C. PBLs were isolated us-
ing a kit (PAA Laboratories; Cölbe, Germany). Blood sam-
ples were layered on Percol 400 and centrifuged at 1200g
for 20min. 5ml PBS was added to the resulting interphase
and centrifuged at 300g for 10min. The separation yielded
~80% PBLs, ~15% monocytes, and ~5% granulocytes.
For IFM, PBLs were fixed in 100% methanol for 0.5h
and permeabilized in 100% acetone for 1min at –20°C.
After washing cells in PBS with 1% fetal calf serum for
1× 10min at room temperature, samples were incubated
with 53BP1 antibody (anti-53BP1, mouse monoclonal;
Merck, Darmstadt, Germany) followed by a secondary
fluorescent antibody (AlexaFluor-488, Invitrogen, Karl-
sruhe, Germany). Samples were mounted using Vectashield
mounting medium (Vector Laboratories, Burlingame, CA,
USA) with DAPI (40,6-diamidino-2-phenylindole). Fluores-
cent images were captured and visually analyzed. A trained
staff member identified and counted the cells until at least
300 cells and 40 foci for each timepoint were registered.
All PBLs in each field of view were analyzed, even those
without evidence of radiation damage.
For TEM, PBL pellets were fixed overnight with 2%
paraformaldehyde and 0.05% glutaraldehyde in PBS. The
ethanol-dehydrated samples were infiltrated with LR Gold
resin (EMS, Hatfield, PA, USA). Afterwards, samples were
embedded in resin containing 0.1% benzyl and kept for 24h
at –20°C followed by ultraviolet light exposure until resin
was polymerized. Ultrathin 70nm slices were sectioned off
the samples using a Microtome Ultracut UCT (Leica, Biel,
Switzerland), picked up on pioloform-coated nickel grids,
and processed for immunogold labeling. To block nonspe-
cific staining, sections were floated on drops of 50mM
glycine and blocking solution. Afterwards, following rins-
ing, sections were incubated with different primary anti-
bodies (53BP1 or pKu70 [anti-pKu70, rabbit polyclonal,
pSer5; Abcam, Cambridge, UK]) overnight at 4 °C. The
same primary antibodies used in fluorescence microscopy
were applied in combination with gold-labeled secondary
antibodies for TEM experiments in order to visualize pKu70
and detect incomplete DNA damage repair sites. A single
IFM focus has a diameter of approximately 1.0µm (Supple-
mentary Figure 8a; green circle). When using gold-labeled
secondary antibodies in the same IFM approach, this focus
consists of two 53BP1 clusters, each one with a diame-
ter of only 500nm (Supplementary Figure 8b; red circles).
In TEM analysis, this focal area can be subdivided fur-
ther into euchromatic and heterochromatic compartments
(Supplementary Figure 8c) and thus allows for reliable de-
tection and quantification of DNA repair factors (Supple-
mentary Figure 8d; pKu70, 10nm, gold beads colored in
red; 53BP1, 6nm, colored in green) and their localization
within different chromatin compartments.
After rinsing, goat secondary antibodies conjugated with
6 and 10nm gold particles (EMS) were applied to the sec-
tions on the grids and then incubated for 1.5h at room
temperature. Subsequently, sections were washed and fix-
ated with 2% glutaraldehyde in PBS. All sections were
stained with uranyl acetate and examined with a Tecnai
BiotwinTM transmission electron microscope (FEI, Eind-
hoven, the Netherlands). For quantification, we identified
pKu70 dimers (two 10nm gold particles) and 53BP1 bead
clusters (6nm) visually at 48,000–86,000×magnification
and counted these in 50 randomly chosen nuclear sections.
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Statistical analysis
A one-sided Mann–Whitney test was performed using the
statistical software OriginPro (version 8.5, OriginLab Cor-
poration, Northampton, USA) to evaluate potential differ-
ences between data groups. The criterion for statistical sig-
nificance was p 0.05.
The dispersion index test was used to determine the de-
viation of foci per cell distribution at the 0.5h datapoint
from Poisson statistics to demonstrate that—in the setting
of partial body irradiation to the head and neck or pelvic
region—only a proportion of PBLs was exposed to irradi-
ation [33, 34]. The test was performed with the software
Dose Estimate, version 3.0 (Chilton, UK).
Results
To characterize the ongoing DNA repair process, PBLs
from nine individuals with head and neck or rectal can-
cer (5 patients received RCT and 4 RT without chemother-
apy) were analyzed by IFM and TEM. Table 1 shows the
patients’ characteristics.
Based on our assumption that the number of irradiation-
induced DSBs depends on the applied dose and irradiation
time, patients were grouped according to cancer type and
the technique applied (patients with head and neck cancers
received IMRT while those with rectal cancers underwent
3D-CRT; Fig. 1a, b). To show the influence of chemother-
apy on DSB formation, patients were further divided into
those who received chemotherapy (n= 5) and those who did
not (n= 4). In total, 40 samples from patients with head and
neck cancer and 45 from patients with rectal cancer (three
technical replicates per sample) were analyzed.
Quantification of initial foci induction by IFM was com-
pleted on samples taken 0.5h after the first RT fraction.
53BP1 foci were not detected in 39 of 432 PBLs (~10%)
from patients with head and neck cancer and in 50 of 517
(~10%) from those with rectal cancer, confirming that par-
tial-body irradiation causes limited PBL exposure (Table 2).
In contrast, no 53BP1 foci could be detected in 85% of the
unirradiated PBLs (in total 2735 from 3222 cells) taken
before the first fraction.
To compare the appearance of 53BP1 foci among sam-
ples from different treatment types, we looked at the PTV
size, radiation duration, and exposed blood volume from
delineated blood vessels (>1cm diameters) encompassed
by the 50% isodose line. Table 2 shows the 53BP1 foci dis-
tribution analysis results measured by IFM 0.5h after the
first RT fraction (observed distribution).
This observed 53BP1 foci distribution did not correspond
with the Poisson statistic as not all PBLs studied during
in vivo radiation passed through the irradiation field and
Table 1 Patients and treatment characteristics according to cancer
type
Category Head & neck cancer Rectal cancer
Total no. of patients 4 5
Age, years
Mean± SD 64± 5 60± 10
Range 60–71 50–74
Sex, no. (%)
Male 3 (75) 3 (60)
Female 1 (25) 2 (40)
KPS, no. (%)
70 – 1 (20)
80 4 (100) 2 (40)
90 – 1 (20)
100 – 1 (20)
T stage, no. (%)
T1 1 (25) –
T2 3 (75) –
T3 – 4 (80)
T4 – 1 (20)
N stage, no. (%)
N0 2 (50) 2 (40)
N1 – 1 (20)
N2 2 (50) 2 (40)
Chemotherapya, no.
(%)
1 (25) 4 (80)
Irradiation technique IMRT
(6 MV photons)
3D-CRT
(18 MV photons)
Irradiation time per fraction
Mean 30min 7min
Total dose, no (%)
46.8Gy – 1 (20)
50.4Gy – 4 (80)
60.0Gy 4 (100) –
PTV, cm3
Mean± SD 1047± 226 1411± 444
D90-PTV, % ref.
dose± SD
89± 6 94± 5
D80-PTV, % ref.
dose± SD
95± 2 97± 3
Isodose volume, cm3
V5iso± SD 6703± 1876 11,961± 1411
V10iso ± SD 5184± 1447 10,030± 1012
V20iso ± SD 3872± 924 7099± 647
V30iso ± SD 2704± 627 5575± 510
V45iso ± SD 1427± 384 2183± 703
Blood volumeb,
cm3± SD
117± 27 173± 44
SD standard deviation, KPS Karnofsky performance score,
PTV planning target volume, T tumor, N node, IMRT intensity
modulated radiotherapy, 3D-CRT 3D-conformal radiotherapy, D dose
aConcurrent chemotherapy regime as described in “Materials and
methods”, three patients with rectal cancer received a neoadjuvant
regimen, one patient received an adjuvant regimen
bDerived from delineated blood vessels >1cm in diameter and
encompassed by the 50% isodose line
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Fig. 1 Representative iso-
dose distribution. a IMRT was
mandatory for patients with
head and neck cancer, with
a predefined arrangement of
seven coplanar beam angles;
b for patients with rectal can-
cer, through 3D-CRT with three
coplanar portals. The irradiated
volume within the violet isodose
(10% reference dose) varies in
size, depending on cancer type
and irradiation modes. IMRT in-
tensity modulated radiotherapy,
3D-CRT 3D-conformal radio-
therapy
therefore foci were not detectable in all cells. To compare
these results, PBLs from healthy donors (lab staff) were
homogenously ex vivo irradiated with 2Gy and 53BP1 foci
quantified 0.5h after irradiation. This 53BP1 foci distribu-
tion did match the Poisson statistic, as shown in Table 2
(Supplementary Table 3).
In addition, a linear dose–response relationship up to
2.0 Gy was demonstrated 0.5h after homogeneous irradi-
ation (0.5–4.0Gy), consistent with the literature [35, 36].
Representative images of cells fixed 0.5h post irradiation
Table 2 Dispersion analysis
of 53BP1 foci distribution 0.5h
after the first RT fraction as mea-
sured by immunofluorescence
Tumor entity 53BP1 yield, foci per cell
0 1 2 3 4 5 6 7 ≥8
Head & neck cancer, no. of cells
Observed distributiona
Mean 39 60 61 91 55 52 26 21 27
±SD 1.38 1.45 1.83 2.83 2.31 1.76 1.62 1.46 1.64
Poisson distribution
Mean 14 48 82 94 80 56 32 16 4
±SD 1.23 1.36 1.24 1.45 1.53 0.87 1.08 1.07 0.34
Rectal cancer, no. of cells
Observed distributionb
Mean 50 66 103 100 81 47 32 17 21
±SD 0.92 1.15 1.51 1.45 1.37 1.01 1.14 0.86 0.89
Poisson distribution
Mean 22 68 108 114 92 58 32 14 8
±SD 0.82 1.19 1.35 1.21 0.89 0.81 0.69 0.86 0.51
a432 PBLs were analyzed in four patients. The resulting distribution after homogeneous ex vivo irradiation
significantly deviates from a Poisson distribution, indicating a partial body irradiation (mean dispersion index
is 1.8± 0.1 (standard error of the mean), U value (standard normal deviate)) is 8.3, and irradiated fraction of
cells is 93% as calculated with the contaminated Poisson method
b517 PBLs were analyzed in five patients. The resulting distribution after homogeneous ex vivo irradiation
significantly deviates from a Poisson distribution, indicating a partial body irradiation (mean dispersion index
is 1.6± 0.1, U value is 6.3, and irradiated fraction of cells is 93% as calculated with the contaminated Poisson
method)
with doses 0, 1, 2, and 4Gy are shown in Fig. 2a and
the associated quantitative dose response data in Fig. 2b.
The time course of 53BP1 focus formation revealed a con-
tinuous 53BP1 foci loss until 24h post exposure (1.0Gy;
Fig. 2c, d; Supplementary Table 4).
Fig. 3a shows the number of 53BP1 foci per cell counted
at each timepoint for all patients stratified by tumor entity
using IFM.
The nonirradiated control (before RT) showed a low
number of foci in patients with head and neck cancer
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Fig. 2 Dose dependence and time course of 53BP1 focus formation. a Immunofluorescence staining for 53BP1 in PBLs analyzed before (non-IR)
and 0.5h after homogeneous irradiation with 1.0, 2.0, or 4.0Gy. b Time kinetics of radiation-induced 53BP1 foci. c, d 53BP1 was visually counted
as number of foci/cells. All points are mean values of three different experiments where at least 300 cells were counted from 10 randomly chosen
fields of view. AsteriskStatistically significant differences (p 0.05) compared with previous values. R2coefficient of determination
(0.37± 0.02 53BP1 foci/cell) and in those with rectal can-
cer (0.33± 0.08 53BP1 foci/cell). At 0.5h after the first RT
fraction, we found a 10-fold rise in the 53BP1 foci number
in head and neck cancer patient samples (3.54± 0.46 53BP1
foci/cell) and rectal cancer patient samples (3.17± 0.40
53BP1 foci/cell). Such a significant increase in the number
of 53BP1 foci in PBLs of cancer patients after therapy
commencement has also been described by Djuzenova
et al. [37].
Over time, PBLs from both groups showed a decline
in foci numbers, although it was still possible to visualize
an average number of 1.46± 0.05 53BP1 foci/cell in PBLs
from head and neck cancer patients and 1.97± 0.17 (~62%)
53BP1 foci/cell in PBLs from rectal cancer patients 24h
after the first fraction (1×; Fig. 3a).
With increasing numbers of administered RT fractions
(up to 30×), the 53BP1 foci accumulated. Patients with
head and neck cancer had 2.49± 0.30 53BP1 foci/cell (5×)
24h after the first week of RT fractions and 4.31± 0.65
53BP1 foci/cell (30×) 24h after further irradiation. Patients
with rectal cancer had 2.81± 0.29 53BP1 foci/cell (5×) and
4.07± 0.44 53BP1 foci/cell (25×), respectively (Fig. 3a).
The 53BP1 foci levels in PBLs of patients with head
and neck cancer tended to outnumber those of patients with
rectal cancer; however, the differences were not significant.
Moreover, we analyzed the number of 53BP1 foci according
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Fig. 3 Quantification of 53BP1 foci by IFM. a The number of 53BP1
foci per PBL nucleus was counted before (non-IR) and 0.5 and 24h af-
ter the first dose fraction (1×) as well as 24h after a predefined number
of additional in vivo irradiation fractions (5× to 30×) to the head and
neck (n= 4) or rectal (n= 5) regions. Data are presented as mean val-
ues of three technical replicates per patient± standard error. b 24h data
during fractionated RT progression, stratified by the administration of
concurrent chemotherapy. Data are presented as mean values of three
technical replicates per patient± standard error; the background num-
ber of foci/cell (control in week 1 before irradiation) was subtracted
from the data. AsteriskSignificant difference to RT patients (p 0.05)
to whether patients received accompanying chemotherapy
(Fig. 3b). Patients receiving chemotherapy had 1.69± 0.16
53BP1 foci/cell 24h after the first RT fraction (1×) and
those without chemotherapy had 1.02± 0.04 53BP1 foci/
cell at the same timepoint. During the course of therapy,
53BP1 accumulated to 2.74± 0.08 foci/cell (5 days after
start of RT) up to 3.78± 0.34 foci/cell (36 days after start of
RT). Without accompanying chemotherapy, 53BP1 foci val-
ues were significantly lower, with 1.70± 0.24 53BP1 foci/
cell (5 days after start of RT) up to 3.17± 0.86 53BP1-foci/
cell (26 days after start of RT).
Quantification of 53BP1 foci by IFM enables estimation
of DNA repair capacity after irradiation exposure. Appli-
cation of TEM analysis improved the resolution of DNA
damage patterns, which are obscured in IFM by the fluo-
rescence of the labeled foci. Quantification of pKu70 and
53BP1 in PBLs after homogeneous ex vivo irradiation ver-
ified the suitability and reliability of the TEM method. Im-
munogold labeling of PBLs for pKu70 (10nm bead size,
colored in red) and 53BP1 (6nm, colored in green) was
completed 0.5h after 1.0Gy irradiation. Colocalization of
53BP1 clusters with pKu70 dimers was observed exclu-
sively in heterochromatic areas. Additionally, pKu70 single
beads and small 53BP1 clusters (2 to 5 beads) were oc-
casionally present at the border between euchromatic and
heterochromatic domains (Fig. 4).
In line with previous data [38], quantification of a dose
response (0.1, 0.5, 1.0, 2.0, or 4.0Gy) 0.5h after irradiation
revealed that the total number of pKu70 dimers and 53BP1
clusters was dose dependent (Fig. 5a, b). Gold bead dimers
and clusters were normalized to nuclear area and section
thickness (pKu70-dimers/µm3 or 53BP1 clusters/µm3).
A straight line correlation from 0.12 pKu70/µm3 (1.0Gy)
up to 3.03 pKu70/µm3 (4.0Gy) with a background signal of
0.10 pKu70/µm3 in nonirradiated PBLs was demonstrated.
The number of induced pKu70 dimers in euchromatin was
consistently lower (from 0.04 pKu70/µm3 at 0.1Gy to 0.65
pKu70/µm3 at 4.0Gy) than those reached in heterochro-
matin (from 0.08 pKu70/µm3 to 2.38 pKu70/µm3). This in-
dicates that 0.5h after irradiation, portions of the originally
induced euchromatic DNA damage were no longer present,
whereas the highest recognition of heterochromatic DSBs
took place at this timepoint. The numbers of 53BP1 clusters
and pKu70 dimers almost correlate completely (from 0.08
53BP1/µm3 to 2.17 53BP1/µm3) due to their colocalization.
Analysis of the time kinetics occurred in the same man-
ner, only at different time points (0.1, 0.25, 0.5, 2.5, 8.0,
and 24h) after homogeneous irradiation with 1.0Gy. High-
est values of pKu70 dimers were observed in euchromatic
compartments after 0.1h (1.44 pKu70/µm3). Ultimately, this
value decreased to 1.03 pKu70/µm3 (~72%) after 0.25h,
to 0.46 pKu70/µm3 (~32%) after 0.5h, to 0.12 pKu70/µm3
(~8%) after 2.5h, to 0.06 pKu70/µm3 (~4%) after 5h, and
to 0.04 pKu70/µm3 (~3%) after 24h (Fig. 5c). These results
suggest that euchromatic DSBs are quickly recognized fol-
lowing irradiation and can be completely repaired within
a few hours. On the contrary, the number of heterochromatic
pKu70 dimers initially rose from 0.10 pKu70/µm3 (0.1h
post-IR) to 0.80 pKu70/µm3 (0.25h post-IR) and to 1.41
pKu70/µm3 (0.5h post-IR). Subsequently, the pKu70 dimers
began to decrease in numbers 2.5h after irradiation to 0.66
pKu70/µm3 (~47%), to 0.32 pKu70/µm3 (~23%) after 8h,
and to 0.16 pKu70/µm3 (~11%) after 24h. The 53BP1 clus-
ters showed roughly the same kinetics as the heterochro-
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Fig. 4 Visualization of pKu70
(10nm beads, pseudo-colored
in red) and 53BP1 (6nm beads,
pseudo-colored in green) 0.5h
after 1Gy irradiation in a repre-
sentative TEM image. Framed
regions shown higher magnifica-
tion in adjacent images
matic pKu70 dimers, with an increase from 0.10 53BP1/µm3
(0.1h post-RT) to 0.80 53BP1/µm3 (0.25h post-IR) and 1.41
53BP1/µm3 (0.5h post-IR). Then, 0.66 53BP1/µm3 (~47%)
53BP1 clusters were detectable after 2.5h and decreased
to 0.34 53BP1/µm3 (~24%) after 8h, and 0.21 53BP1/µm3
(~15%) were still visible after 24h (Fig. 5d). Additionally,
53BP1 clusters, consisting of 5 to 12 gold beads and with-
out pKu70 colocalization, were observed 8 and 24h after
irradiation, potentially marking chromatin changes in areas
where DNA damage was present.
To expand our knowledge on DNA damage, we investi-
gated PBLs of patients with head and neck cancer after RT
and RCT using TEM, before and 0.1, 0.5, and 24h after
the first fraction, by quantifying pKu70 dimers and 53BP1
clusters in euchromatin and heterochromatin of 50 nuclear
sections per sample. Fig. 6a, b show representative TEM
micrographs.
Visualization of 10nm (pKu70 dimers) and 6nm gold
beads (53BP1 cluster) was improved by overlaying with
red and green circles, respectively. The RCT patient showed
a higher level of repair proteins than the RT patient in both
chromatin domains (Fig. 7a–d) 0.5 and 24h after the first
fraction.
There was no difference between RT and RCT be-
fore and 0.1h after in vivo irradiation in terms of the
number of pKu70 dimers/μm3, with RT: 0.15± 0.01 and
RCT: 0.11± 0.01 compared to RT: 1.75± 0.03 and RCT:
1.76± 0.04. However, detection of 53BP1 showed sig-
nificantly higher values for RCT patients, both 0.5 and
24h after in vivo irradiation (Fig. 7d and Supplementary
Table 5).
Discussion
In this study, we questioned whether the DNA damage re-
pair in PBLs during radiotherapy for head and neck or
rectal cancers is influenced by simultaneous chemother-
apy or other variables, such as isodose volume, irradia-
tion time, or by different irradiation techniques (IMRT or
3D-CRT). Additionally, we investigated how repetitive het-
erogeneous dose exposure influences the radiation-induced
DNA damage of PBLs, especially in patients prescribed
with concomitant chemotherapeutics. To do this, we quan-
tified 53BP1 foci formation [13, 14] in irradiated PBLs, and
found that not every 53BP1 focus equates to an unrepaired
DSB.
IFM is a well-established method to visualize and ana-
lyze DNA repair proteins. It has the advantage of allowing
fast examination of many cells. However, this is only possi-
ble for repair factors that accumulate in the vicinity of DSBs
in sufficient number, thereby producing adequate fluores-
cent signals. IFM cannot be used to detect pKu70, which
binds as a heterodimer with pKu80 at the ends of DSBs
[4, 38]. Visualization of 53BP1 foci using IFM indicates
DSBs; however, persisting 53BP1 foci mean fluorescence
K
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Fig. 5 Quantification of pKu70 dimers and 53BP1 clusters by TEM after homogeneous irradiation with 1.0Gy. Quantification of pKu70 dimers
and 53BP1 clusters (quantified in ≥50 nuclear sections) in euchromatin (red) and heterochromatin (green) 0.5h after irradiation with different
doses (a, b) and at different timepoints after irradiation with 2Gy (c, d). R2coefficient of determination
signals may still be detectable after the initial damage has
been repaired. TEM enables clarification of the repair status
of a DSB as it allows for detection of pKu70, the central
repair protein of the NHEJ, which signals incomplete DNA
damage repair.
Following homogeneous in vitro PBL irradiation, IFM
showed a linear 53BP1 dose correlation 0.5h post-IR up
to 2Gy (Fig. 2c) and TEM showed similar correlation up
to 4Gy (Fig. 5b). With increasing doses (>2Gy), the fluo-
rescent signal of individual adjacent foci overlapped, mak-
ing IFM quantification difficult if not almost impossible
(Fig. 2a). This limitation does not occur with quantitative
TEM as gold beads were either present and quantifiable or
absent. However, when LR Gold resin-embedded PBL sec-
tions are investigated and quantified using TEM, it is critical
to always consider that only planar sections of the nucleus
are examined and not the entire cell nucleus. To gain greater
insight into the number of gold-labeled repair proteins in the
entire nucleus, the labeling in 50-nuclei sections per dose
or repair timepoint was quantified. Additionally, nonhomo-
geneously distributed pKu70 dimers and 53BP1 clusters in
the cell nucleus over the number of nuclei sections was cap-
tured as reliably as possible by counting all 10 nm (pKu70)
and 6 nm (53BP1) gold beads. The distance of a 10 nm gold
bead from the antigen or repair protein is a maximum of
28nm (Supplementary Figure 9). In contrast, IFM enabled
visualization and quantification of foci in each entire PBL
nucleus. The primary antibodies and the fluorochrome-cou-
pled secondary antibodies penetrated the fixed cells and cell
nuclei due to the permeabilization step (acetone, 1min at
–20°C). In IFM, the degree to which cell structures were
preserved after this chemical treatment was not detectable
K
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Fig. 6 Visualization of pKu70 (10nm beads, pseudo-colored in red)
and 53BP1 (6nm beads, pseudo-colored in green) in peripheral blood
lymphocytes (PBLs) 24h after first RT (a) and RCT (b)
by means of the DAPI signal. No other publications have
reported on the structural preservation and quality of cells
after IFM sample preparation. After sectioning embedded
PBLs, immunogold-labeled repair proteins were visualized
and quantified in TEM. Permeabilization was not necessary,
as antigens were found freely accessible near the surface.
All cell structures (membranes, mitochondria, etc.) were
perfectly visible in TEM and optimally preserved.
PBLs, which are often used for biological dosimetry [39]
and for determination of individual radiosensitivity [40, 41],
do not go through the cell cycle but remain in the G0
phase. Several studies have shown that PBLs sometimes
undergo apoptosis 12–24h after irradiation, which is char-
acterized by significant chromatin condensation [35, 42].
This apoptotic chromatin condensation within human PBLs
may prevent decomposition of residual DNA repair foci,
which were observed in PBLs 24h after irradiation [43]. Ir-
radiation-induced residual foci in condensed chromatin can
persist longer than 24h in apoptotic G0 PBLs. Persisting
foci are not to be confused with existing DSBs, as these
especially slow repaired or unrepaired DSBs are eventually
responsible for induction of apoptosis. Moreover, pulsed-
field gel electrophoresis and confocal laser microscopy ex-
periments have shown that in normal human fibroblasts, re-
pair of existing DSBs does not correspond with the counted
53BP1 foci [44]. Our results confirm this, as 24h after
irradiation, 53BP1 clusters often did not colocalize with
pKu70 (Fig. 6a, b). As we have already reported, DSBs
can be visualized by pKu70 dimers [30, 38] that bind di-
rectly to the ends of DSBs. In TEM, lack of pKu70 within
a 53BP1 cluster indicates the absence of a DSB at this
point. Therefore, the frequency of colocalizations between
pKu70 and 53BP1 is largely dependent on the point in time
post irradiation. The recorded accumulation of 53BP1 foci
by IFM in Fig. 3a, after an increasing number of applied
fractions, is probably due to a mixture of newly induced
DSBs per daily fraction and the generation of persistent
chromatin changes after unfinished or defective DSB re-
pairs. Loss of 53BP1 foci occurs through apoptosis of aged
or damaged PBLs and the successful repair of DSBs [41,
44]. However, as an overall (but not linear) increase in the
number of 53BP1 foci was observed, especially 24h post-
IR between the first (1×) and last (25× or 30×) fraction,
it is reasonable to assume that at this timepoint, accumu-
lation of persisting 53BP1 foci was significantly involved,
whereas during the previous 24h, more repairable DSBs
were eliminated. A continuous but not smooth increase in
53BP1 foci was detected throughout the entire treatment
period—possibly due to a mixing of the opposing events
of DSB induction, their repair, and the appearance of resid-
ual 53BP1 foci within a period of 24h. Additionally, new
PBLs formed over the period of 30 fractions. At the time
of blood sampling, these may have crossed the irradiation
field only once or even not at all, which is why, accord-
ingly, no or only initial 53BP1 foci were detected in these
PBLs. By contrast, initial and residual 53BP1 foci can be
detected in older PBLs and moreover, older and damaged
PBLs are preferentially eliminated through apoptosis. Fur-
thermore, RT has immunomodulatory properties, the extent
of which is determined by the radiation dose administered,
the concomitant chemotherapy, and the immune system of
K
Strahlenther Onkol (2020) 196:821–833 831
Fig. 7 Quantification of pKu70
dimers and 53BP1 clusters by
TEM in PBLs of patients who
received RT or RCT. TEM quan-
tification of pKu70 dimers per
µm3 in total chromatin (a), eu-
chromatin (b), and heterochro-
matin (c) following RT or RCT.
Additionally, the number of
53BP1 beads per µm3 was quan-
tified in PBLs of RT and RCT
patients 0.1, 0.5, and 24h after
the first radiation fraction (d).
Asterisk Statistically significant
differences (p 0.05) compared
with previous values
the patient. As such, occurrence and repair of DNA dam-
age in the PBLs of patients is determined by a range of
influencing factors that are in turn influenced by external
parameters (different techniques for application of radia-
tion, isodose volumes, dose applied, duration of radiation
application, and concomitant chemotherapy) and internal
influencing factors (immune system, individual capacity for
DNA repair) [45, 46]. Thus, it is not possible to evaluate the
repair capacity based on a rise in 53BP1 foci detected 24h
after irradiation. Most persistent 53BP1 foci responsible for
the increase are located exclusively in the periphery of het-
erochromatin domains and contain no pKu70. Most likely,
these represent apoptotic processes rather than unrepaired
DSBs. In Fig. 3b, we show higher 53BP1 foci levels for all
patients who received RCT, independent of the collective.
The cytotoxic effects of chemotherapy drugs have been de-
scribed at length in the literature, whereby their objective
is to induce DNA damage and activate apoptosis [47, 48].
By using the higher resolution of TEM in combination
with the immunogold labeling of pKu70 and 53BP1 within
the intact nuclear cell ultrastructure, we were able to detect
a higher number of pKu70 dimers in the euchromatin and
heterochromatin of PBLs in RCT patients than in those of
patients after a single RT 24h post-IR. In addition, we vi-
sualized pKu70 dimers individually as well as collectively
(2× or 3× pKu70 dimers), which suggests multiple DSBs in
close proximity (Fig. 6). These results indicate that the scale
of DNA damage induced during radiotherapy is affected
by the presence of accompanying chemotherapy. Thus, the
number of DSBs in PBLs was not significantly influenced
by the irradiation technique (IMRT or 3D-CRT) or the size
of the irradiation field. This, however, could be due to the
possibility that effects induced by IMRT, in which a smaller
PTV is irradiated over a longer period of time, counterbal-
ance those induced in 3D-CRT, in which a larger volume is
irradiated over a shorter time period.
Based on these data, we propose that persisting DSBs
(pKu70 dimers) represent more severe damage induced
by RCT (1, 2, or more pKu70 dimers representing multiple
DNA lesions). Repair seems to be difficult or even impossi-
ble in these cells. A large-scale study is necessary to be able
to better study the cause of this observation, in particular
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to clarify how the concomitant chemotherapy prolongs the
dwell time of existing DSBs in PBLs that are located in the
G0 phase of the cell cycle. In addition, as persistent DSBs
were detectable only at certain times >0.5h after irradia-
tion and always at the edge of heterochromatic domains,
we suspect that cellular processes, such as the opening
of densely packed heterochromatic regions containing one
or more DSBs, delay repair. However, not every residual
focus is equivalent to a remaining DSB, since pKu70 was
not present at every damage site. Persistent 53BP1 clusters
without colocalizing pKu70 are likely to show chromatin
alterations after completion or possibly defective repair.
Therefore, IFM 53BP1 foci analyses alone are not ade-
quate to determine the individual repair capacity after the
irradiation of PBLs, as a DSB may be marked by a 53BP1
focus but not every 53BP1 focus represents a DSB.
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